Genscript Biotech Corporation - Asset Resilience Ratio
Genscript Biotech Corporation (G51) has an Asset Resilience Ratio of 11.87% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read G51 liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2024)
This chart shows how Genscript Biotech Corporation's Asset Resilience Ratio has changed over time. See Genscript Biotech Corporation (G51) shareholders funds for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Genscript Biotech Corporation's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Genscript Biotech Corporation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €645.15 Million | 11.87% |
| Total Liquid Assets | €645.15 Million | 11.87% |
Asset Resilience Insights
- Moderate Liquidity: Genscript Biotech Corporation has 11.87% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Genscript Biotech Corporation Industry Peers by Asset Resilience Ratio
Compare Genscript Biotech Corporation's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Argen-X
F:1AE |
Biotechnology | 25.67% |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229 |
Biotechnology | 0.21% |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333 |
Biotechnology | 35.96% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.48% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 70.49% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
Annual Asset Resilience Ratio for Genscript Biotech Corporation (2017–2024)
The table below shows the annual Asset Resilience Ratio data for Genscript Biotech Corporation.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 9.27% | €489.19 Million ≈ $571.92 Million |
€5.28 Billion ≈ $6.17 Billion |
-4.95pp |
| 2023-12-31 | 14.22% | €481.65 Million ≈ $563.10 Million |
€3.39 Billion ≈ $3.96 Billion |
-3.03pp |
| 2022-12-31 | 17.25% | €439.33 Million ≈ $513.62 Million |
€2.55 Billion ≈ $2.98 Billion |
+7.30pp |
| 2021-12-31 | 9.95% | €222.23 Million ≈ $259.81 Million |
€2.23 Billion ≈ $2.61 Billion |
+0.13pp |
| 2020-12-31 | 9.82% | €142.11 Million ≈ $166.14 Million |
€1.45 Billion ≈ $1.69 Billion |
-9.76pp |
| 2019-12-31 | 19.58% | €174.13 Million ≈ $203.57 Million |
€889.41 Million ≈ $1.04 Billion |
+11.94pp |
| 2018-12-31 | 7.64% | €70.06 Million ≈ $81.90 Million |
€916.98 Million ≈ $1.07 Billion |
+7.03pp |
| 2017-12-31 | 0.61% | €3.09 Million ≈ $3.61 Million |
€504.26 Million ≈ $589.54 Million |
-- |
About Genscript Biotech Corporation
Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in the United States of America, Europe, Mainland China, Europe, Asia Pacific, and internationally. It operates through three segments: Life Science Services and Products; Biologics Development Services; and Industrial Synthetic Biology Products. The Lif… Read more